Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Market

Jun 22, 2020

10 likes | 106 Views

The total diagnosed prevalent population of Familial Hypercholesterolemia (FH) in the 7MM was 965,405 in 2017, which is anticipated to increase by 2030. Also, the diagnosed prevalent population of FH was found to be 244,214 in the United States during the same period. The market size of Familial Hypercholesterolemia in the 7MM was found to be USD 1,069.27 Million in 2017. Emerging therapies and promising organizations are some of the key factors expected to drive the FH market in the coming years, while late diagnosis, differential diagnosis, lack of Homozygous FH (HoFH) are major barriers in the advancement of the Familial Hypercholesterolemia market. The key players in the Familial Hypercholesterolemia market includes Regeneron Pharmaceuticals, Novartis, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Madrigal Pharmaceuticals, and others. For more information visit: https://www.delveinsight.com/report-store/familial-hypercholesterolemia-type-ii-hyperlipoproteinemia-market

DelveInsight

Download Presentation

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D